These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14593295)

  • 1. [Comments on the Women's Health Initiative (WHI) and the Million Women Study (MWS) which question the usefulness of hormone substitution during menopause].
    Lopes P
    J Gynecol Obstet Biol Reprod (Paris); 2003 Oct; 32(6):500-2. PubMed ID: 14593295
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks of hormone therapy in the 50-59 year age group.
    van de Weijer PH
    Maturitas; 2008 May; 60(1):59-64. PubMed ID: 18556157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?
    Mikkola TS; Clarkson TB; Notelovitz M
    Ann Med; 2004; 36(6):402-13. PubMed ID: 15513292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy: dilemmas in 2002.
    Moore A
    Trans Am Clin Climatol Assoc; 2003; 114():233-8; discussion 238-40. PubMed ID: 12813923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
    Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
    Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A personal initiative for women's health: to challenge the Women's Health Initiative.
    Genazzani AR; Gambacciani M
    Gynecol Endocrinol; 2002 Aug; 16(4):255-7. PubMed ID: 12396552
    [No Abstract]   [Full Text] [Related]  

  • 7. Pitfalls of the WHIs: Women's Health Initiative.
    Mastorakos G; Sakkas EG; Xydakis AM; Creatsas G
    Ann N Y Acad Sci; 2006 Dec; 1092():331-40. PubMed ID: 17308158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHI risks: any relevance to menopause management?
    Burger HG
    Maturitas; 2007 May; 57(1):6-10. PubMed ID: 17368974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Where are we with postmenopausal hormone therapy in 2005?
    Lam PM; Chung TK; Haines C
    Gynecol Endocrinol; 2005 Nov; 21(5):248-56. PubMed ID: 16373243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F; Taylor HS; Karas R; Brinton E; Newman I; Clarkson TB; Mendelsohn M; Lobo RA; Judelson DR; Nachtigall LE; Heward CB; Hecht H; Jaff MR; Harman SM;
    Fertil Steril; 2004 Jun; 81(6):1498-501. PubMed ID: 15193467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging facade of menopausal hormone therapy.
    Rees M
    Semin Reprod Med; 2010 Sep; 28(5):351-9. PubMed ID: 20845235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIH and WHI: time for a mea culpa and steps beyond.
    Utian WH
    Menopause; 2007; 14(6):1056-9. PubMed ID: 17975521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone replacement therapy post Women's Health Initiative study: where do we stand?
    Calleja-Agius J; Brincat MP
    Curr Opin Obstet Gynecol; 2008 Dec; 20(6):513-8. PubMed ID: 18989125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on hormones, menopause, and heart disease: evaluating professional responses to the Women's Health Initiative.
    Derry PS
    Health Care Women Int; 2008 Aug; 29(7):720-37. PubMed ID: 18663631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinician's review of the WHI-related literature.
    Speroff L
    Int J Fertil Womens Med; 2004; 49(6):252-67. PubMed ID: 15751264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Wenger NK
    Pediatr Blood Cancer; 2005 Jun; 44(7):625-9. PubMed ID: 15747336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.